The name is absent



84

criteria and have been recruited in the protocol. Of them, 164 participants exhibited
one out of eight sarcoma subtypes related with an intermediate prognosis and only 15
exhibited one out of two subtypes of the disease related to good prognosis. No patient
with a sarcoma subtype related to poor prognosis has been reported yet. Table 4.1
shows the available data.

Table 4.1: Reported number of successes∕trials for each one of the sarcoma subtypes.

Intermediate Prognosis
subtype successes∕trials
Leiomyosarcoma 6/28

Liposarcoma 7/29
MFH 3/29
Osteosarcoma 5/26
Synovial 3/20
Angiosarcoma 2/15
MPNST 1/5
Fibrosarcoma 1/12
Good Prognosis
Ewing’s 0/13
Rhabdo 0/2

4.3 Non-Exchangeable Product Partition Model

4.3.1 Model Definition

Let yi and N1 respectively denote the number of successes (i.e., patients with positive
outcome) and the total number of patients presenting with sarcoma subtype
i, i =



More intriguing information

1. The name is absent
2. The name is absent
3. The name is absent
4. The name is absent
5. AJAE Appendix: Willingness to Pay Versus Expected Consumption Value in Vickrey Auctions for New Experience Goods
6. From Communication to Presence: Cognition, Emotions and Culture towards the Ultimate Communicative Experience. Festschrift in honor of Luigi Anolli
7. Regional specialisation in a transition country - Hungary
8. Three Policies to Improve Productivity Growth in Canada
9. The demand for urban transport: An application of discrete choice model for Cadiz
10. The name is absent
11. Fighting windmills? EU industrial interests and global climate negotiations
12. CROSS-COMMODITY PERSPECTIVE ON CONTRACTING: EVIDENCE FROM MISSISSIPPI
13. On the estimation of hospital cost: the approach
14. The name is absent
15. Brauchen wir ein Konjunkturprogramm?: Kommentar
16. Income Growth and Mobility of Rural Households in Kenya: Role of Education and Historical Patterns in Poverty Reduction
17. Gender and headship in the twenty-first century
18. Trade Openness and Volatility
19. The name is absent
20. Outsourcing, Complementary Innovations and Growth